Background Gliomas are brain tumours arising from glial cells with an annual incidence of 4
to 11 people per 100,000. In this review we focus on gliomas with low aggressive potential …

Abstract WHO grade II-III gliomas are rare primary brain tumors occurring at a median age of
about 35–55 years. Median survival is longer in WHO grade II-III glioma compared with …

Background Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting
molecular heterogeneity of the disease. We compared two different, single-modality …

The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH)
mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades …

Background In isocitrate dehydrogenase (IDH)-mutant low-grade gliomas (LGGs), awake
functional-based resection (ie, resection based on intraoperative functional responses rather …

Background Bevacizumab is increasingly used in children with pediatric low-grade glioma
(PLGG) despite limited evidence. A nationwide UK service evaluation was conducted to …

Background Temozolomide chemotherapy versus radiotherapy in patients with a high-risk
low-grade glioma has been shown to have no significant effect on progression-free survival …

Objective For a long time, return to work (RTW) has been neglected in patients harboring a
diffuse low-grade glioma (LGG). However, a majority of LGG patients worked at time of …

Background The median survival of glioblastoma is 12–14 months with less than 10% of
patients surviving at least 2 years from diagnosis. Patients diagnosed with glioblastoma face …

Context Caring for a family member with advanced cancer strains family caregivers.
Classification of family types has been shown to identify patients at risk of poor psychosocial …